Cardio Diagnostics Holdings (NASDAQ: CDIO) stock is up 123% on the day, and also 860% over the past month. We’re all used to flurries, ramps of speculation, in small cap pharma stocks. Sometimes there’s even a real and substantive reason behind such price changes. Which is, of course, why there are so many speculations which might not have a substantive reason behind them. If we’re all primed for the possibility that something real might happen then we’re vulnerable to claims that might not be wholly and entirely true.
Cardio Diagnostics does seem to have something here. Whether it’s worth quite as much as the market currently thinks is another matter, but something real, yes. For example, they’re able to sign up to sell it in India: “Aimil Ltd., one of the companies at the forefront of India’s instrumentation industry, is a leader in introducing innovative technologies to their extensive healthcare network in India. A new Supply and Distribution Agreement with Cardio Diagnostics (NASDAQ: CDIO) has the potential to further these efforts and transform global cardiovascular healthcare in the process.”
Cardio also has an agreement with Vizient: “Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ:CDIO) are skyrocketing on Tuesday following the announcement of a key deal. Specifically, Vizient has awarded Cardio Diagnostics an “Innovation Technology” contract for its artificial intelligence (AI) driven molecular heart disease tests. As of this writing, CDIO stock is up more than 45% on the news. Nevertheless, prospective investors should realize that significant challenges still lie ahead for the firm.” Note that “rocketing” was three weeks back.
Cardio Diagnostics Holdings stock price from Google Finance
So, that premarketing seems to be working, the market positioning is underway. But of course it’s also necessary for the tests to actually work. Which is what has driven this last doubling of the Cardio stock price: “Dr. Dogan added that “this study marks a significant step forward in CHD diagnosis, leveraging the synergies of genetics, epigenetics, and AI to offer a highly sensitive, efficient, scalable and personalized approach for CHD care.” She noted that “because the test was also recently awarded an Innovation Technology contract from Vizient, the nation’s largest group purchasing organization, clinicians at 60% of hospitals and 97% of academic medical centers in the United States already have access to the test.”” The full paper is here.
Now, yes, there is a certain amount of hype here. There’s that continued mention of “AI” which is very much the flavour of the week. Yet it’s also true that this is exactly where AI is expected to be useful - pattern recognition is exactly what AI does and an awful lot of diagnostics in pattern recognition.
We’d not think it wise to go overboard here, but it does look like Cardio Diagnostics has something real and potentially valuable here.